NIH funding cuts delayed a promising childhood brain cancer trial. Patients lost time they didn't have.

Published 25 Sep 2026, 11:05 UTC. Updated 26 Sep 2026, 18:05 UTC.

A delayed clinical trial underscores the stakes of federal research funding cuts for children with DIPG, a deadly brain tumor with few treatment options.

Directly affected

No company is named in this report.

Indirectly affected

ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
CRDF CARDIFF ONCOLOGY INC COM
GA selected CRDF as a RELATED security because its canonical security name directly matches this event's themes: oncology. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
DVA DaVita HealthCare Partners, Inc.
GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.

Price reaction, T-5 to T+3

Ticker	T-5	T-3	T-1	T0	T+1	T+2	T+3
ACHC	—	—	—	—	—	—	—
ASND	—	—	—	—	—	—	—
ATYR	—	—	—	—	—	—	—
BBIO	—	—	—	—	—	—	—
CRDF	—	—	—	—	—	—	—
DVA	—	—	—	—	—	—	—

A delayed clinical trial underscores the stakes of federal research funding cuts for children with DIPG, a deadly brain tumor with few treatment options.

Source: CNBC Top

The price since 25 Sep 2026: Acadia Healthcare (ACHC) versus the S&P 500

Since the first closing price after “NIH funding cuts delayed a promising childhood brain cancer trial. Patients lost time they didn't have.,” Acadia Healthcare (ACHC) is +8.13%. The S&P 500 fund (SPY) is +0.15% over the same days, a +7.98% difference versus the market.

ACHC

SPY

Filings that name Acadia Healthcare (ACHC) around 25 Sep 2026

Gilbert Cisneros sell BridgeBio Pharma (BBIO) ($1,001 - $15,000). That is 4 days after publication, inside 30 days. The filing is listed beside the story “NIH funding cuts delayed a promising childhood brain cancer trial. Patients lost time they didn't have..”

Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).

Who gains and who loses around Acadia Healthcare (ACHC)

Companies tied to this story

ACHC Acadia Healthcare
In “NIH funding cuts delayed a promising childhood brain cancer trial. Patients lost time they didn't have.,” Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
ASND Ascendis Pharma A/S
In “NIH funding cuts delayed a promising childhood brain cancer trial. Patients lost time they didn't have.,” Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence. Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
ATYR aTYR PHARMA
In “NIH funding cuts delayed a promising childhood brain cancer trial. Patients lost time they didn't have.,” aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence. Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
BBIO BridgeBio Pharma
For “NIH funding cuts delayed a promising childhood brain cancer trial. Patients lost time they didn't have.,” BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence. Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
CRDF Cardiff Oncology
For “NIH funding cuts delayed a promising childhood brain cancer trial. Patients lost time they didn't have.,” Cardiff Oncology (CRDF) is linked, with no stored direction, medium confidence. Reason on file: GA selected CRDF as a RELATED security because its canonical security name directly matches this event's themes: oncology. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
DVA Davita
Davita (DVA) is linked, with no stored direction, medium confidence in the 25 Sep 2026 story “NIH funding cuts delayed a promising childhood brain cancer trial. Patients lost time they didn't have..” Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article

Acadia Healthcare (ACHC)

On 25 Sep 2026, “NIH funding cuts delayed a promising childhood brain cancer trial. Patients lost time they didn't have.” is the story that connects Acadia Healthcare (ACHC) to this story.

For Acadia Healthcare (ACHC), the reason on file says GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article

Also listed, Ascendis Pharma A/S (ASND): GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article

Dates and price levels for Acadia Healthcare (ACHC)

ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. ASND traded between 219.69 and 240.84 across 20 sessions. The latest close on file is 229.99. ATYR traded between 0.17 and 0.41 across 20 sessions. The latest close on file is 0.17.

How strong the case is around Acadia Healthcare (ACHC)

46 out of 100

“NIH funding cuts delayed a promising childhood brain cancer trial. Patients lost time they didn't have.” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.